

Clinical trials of rimonabant

TrialResults-center www.trialresultscenter.org

1 cardiovascular prevention

Trial	Treatments	Patients	Trials design and methods
rimonabant vs placebo			
STRADIVARIUS , 2008 [NCT00124332] n=NA follow-up:	rimonabant 20 mg daily versus placebo	patients with abdominal obesity and the metabolic syndrome	Parallel groups double-blind North America, Europe, and Australia
CRESCENDO , 2010 [NCT00263042] n=9381/9314 follow-up: 13.8 months	rimonabant 20 mg versus placebo	patients patients with abdominal obesity and with previously manifest or increased risk of vascular disease	Parallel groups double-blind 42 countries
AUDITOR <i>ongoing</i> n=NA	-	-	
rimonabant 20mg vs placebo			
RIO europe 20mg , 2005 n=599/305 follow-up:	rimonabant 20mg daily versus placebo	patients with body-mass index 30 kg/m2 or greater, or body-mass index greater than 27 kg/m2 with treated or untreated dyslipidaemia, hypertension, or botht-dt	Parallel groups Double blind Europe and USA
Rio-lipid 20 mg , 2005 n=346/342 follow-up: 12 months	rimonabant 20 mg daily versus placebo	overweight or obese patients (body-mass index 27 to 40) with untreated dyslipidemia (triglyceride levels >1.69 to 7.90 mmol per liter, or a ratio of cholesterol to high-density lipoprotein [HDL] cholesterol of >4.5 among women and >5 among men)	Parallel groups Double blind worlwide (8 countries)
RIO-North America 20 mg , 2006 [NCT00029861] n=1222/607 follow-up:	rimonabant 20mg daily versus placebo	obese (body mass index >=30) or overweight (body mass index >=27 and treated or untreated hypertension or dyslipidemia) adult patients	Parallel groups Double blind US and Canada
rimonabant 5mg vs placebo			

continued...

Trial	Treatments	Patients	Trials design and methods
RIO europe 5mg , 2005 n=603/305 follow-up: 1 y	5 mg rimonabant versus placebo	patients with body-mass index 30 kg/m2 or greater, or body-mass index greater than 27 kg/m2 with treated or untreated dyslipidaemia, hypertension, or both	Parallel groups double-blind
rimonabant 20mg vs rimonabant 5mg			
RIO europe (20 vs 5 mg) , 2005 n=599/603 follow-up:	-	-	

More details and results :

- weight-loss drugs for cardiovascular prevention in overweight or obese patients at <http://www.trialresultscenter.org/go-Q444>

References

STRADIVARIUS, 2008:

Nissen SE, Nicholls SJ, Wolski K, Rods-Cabau J, Cannon CP, Deanfield JE, Desprs JP, Kastelein JJ, Steinhubl SR, Kapadia S, Yasin M, Ruzyllo W, Gaudin C, Job B, Hu B, Bhatt DL, Lincoff AM, Tuzcu EM Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA 2008 Apr 2;299:1547-60 [18387931]

CRESCENDO, 2010:

Topol EJ, Bousser MG, Fox KA, Creager MA, Despres JP, Easton JD, Hamm CW, Montalescot G, Steg PG, Pearson TA, Cohen E, Gaudin C, Job B, Murphy JH, Bhatt DL Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet 2010 Aug 14;376:517-23 [20709233] 10.1016/S0140-6736(10)60935-X

AUDITOR, 0:

ongoing trial

RIO europe 20mg, 2005:

Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005 Apr 16-22;365:1389-97 [15836887]

Rio-lipid 20 mg, 2005:

Despres JP, Golay A, Sjostrom L Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005 Nov 17;353:2121-34 [16291982]

RIO-North America 20 mg, 2006:

Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J, , Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006;295:761-75. [16478899] 10.1001/jama.295.7.761

RIO europe 5mg, 2005:

Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005 Apr 16-22;365:1389-97 [15836887]

RIO europe (20 vs 5 mg), 2005:

Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005 Apr 16-22;365:1389-97 [[15836887](#)]

Entry terms: rimonabant, SR141716, SR 141716, Acomplia, Zimulti, Sanofi-Synthelabo brand of rimonabant, SR 141716A, SR141716A, SR-141716A,